Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares saw an uptick in trading volume on Thursday . 689,910 shares were traded during trading, a decline of 19% from the previous session’s volume of 848,702 shares.The stock last traded at $49.31 and had previously closed at $50.85.

A number of research firms have recently commented on RARE. Jefferies Group restated a “buy” rating and set a $109.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, May 10th. Leerink Swann restated a “buy” rating and set a $85.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday. Canaccord Genuity restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, May 10th. Zacks Investment Research upgraded shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Wednesday, May 4th. Finally, Cowen and Company reiterated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research note on Friday. Three research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $98.09.

The company has a 50-day moving average of $58.02 and a 200 day moving average of $65.17. The firm’s market cap is $2.07 billion.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Monday, May 9th. The biopharmaceutical company reported ($1.35) EPS for the quarter, missing the consensus estimate of ($1.29) by $0.06. During the same period in the prior year, the company earned ($0.63) EPS. Ultragenyx Pharmaceutical’s revenue was up .0% on a year-over-year basis. Equities analysts predict that Ultragenyx Pharmaceutical Inc. will post ($5.84) EPS for the current fiscal year.

In other Ultragenyx Pharmaceutical news, insider Sunil Agarwal sold 650 shares of the company’s stock in a transaction dated Monday, June 20th. The shares were sold at an average price of $54.16, for a total value of $35,204.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Emil D. Kakkis sold 20,000 shares of the company’s stock in a transaction dated Monday, May 16th. The stock was sold at an average price of $59.95, for a total transaction of $1,199,000.00. Following the completion of the sale, the chief executive officer now directly owns 526,704 shares of the company’s stock, valued at $31,575,904.80. The disclosure for this sale can be found here.

Other large investors have recently modified their holdings of the company. Russell Frank Co increased its stake in shares of Ultragenyx Pharmaceutical by 425.8% in the fourth quarter. Russell Frank Co now owns 13,523 shares of the biopharmaceutical company’s stock worth $1,529,000 after buying an additional 10,951 shares during the last quarter. State Board of Administration of Florida Retirement System increased its stake in shares of Ultragenyx Pharmaceutical by 6.7% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 22,007 shares of the biopharmaceutical company’s stock worth $2,469,000 after buying an additional 1,390 shares during the last quarter. American Century Companies Inc. increased its stake in shares of Ultragenyx Pharmaceutical by 14.4% in the fourth quarter. American Century Companies Inc. now owns 39,156 shares of the biopharmaceutical company’s stock worth $4,393,000 after buying an additional 4,943 shares during the last quarter. Swiss National Bank increased its stake in shares of Ultragenyx Pharmaceutical by 1.4% in the fourth quarter. Swiss National Bank now owns 35,367 shares of the biopharmaceutical company’s stock worth $3,967,000 after buying an additional 500 shares during the last quarter. Finally, Rhumbline Advisers increased its stake in shares of Ultragenyx Pharmaceutical by 9.1% in the fourth quarter. Rhumbline Advisers now owns 39,116 shares of the biopharmaceutical company’s stock worth $4,388,000 after buying an additional 3,266 shares during the last quarter.

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.